<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-37376" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>PCSK9 Inhibitors</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pokhrel</surname>
            <given-names>Binod</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pellegrini</surname>
            <given-names>Mark V.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Levine</surname>
            <given-names>Steven N.</given-names>
          </name>
          <aff>LSU Health Sciences Center Shreveport</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Binod Pokhrel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Pellegrini declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Steven Levine declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-37376.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an important regulator of cholesterol metabolism. In the United States, 2 fully humanized monoclonal antibodies&#x02014;alirocumab and evolocumab&#x02014; have been approved by the US Food and Drug Administration (FDA) to inhibit or reduce PCSK9 activity. Recently, both the European Union and FDA have approved inclisiran, a small interfering mRNA, that inhibits intracellular PCSK9 synthesis. Increased PCSK9 activity correlates with heightened LDL-C levels, while specific gain-of-function mutations lead to autosomal dominant familial hypercholesterolemia characterized by extremely high total and low-density lipoprotein (LDL) cholesterol levels, premature atherosclerotic vascular disease, and the formation of tendon xanthomas. In most cases, this is due to a genetic mutation of the LDL receptor caused by mutations of the apoprotein <italic toggle="yes">B100</italic> or <italic toggle="yes">PCSK9</italic> genes. Conversely, individuals with reduced PCSK9 activity, whether&#x000a0;due to&#x000a0;genetic polymorphism or the administration of PCSK9 monoclonal antibodies, exhibit lower cholesterol levels and a reduced risk of cardiovascular disease. This activity outlines&#x000a0;the indications, mechanism of action, administration methods, significant adverse effects, contraindications, monitoring, and toxicity of PCSK9 inhibitors. This activity also helps the interprofessional healthcare team tailor patient therapy for optimal outcomes in serum lipid management and improve cardiovascular outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients with familial&#x000a0;hypercholesterolemia who may benefit from PCSK9 inhibitor therapy based on their lipid profile and cardiovascular risk factors.</p></list-item><list-item><p>Implement evidence-based practices for initiating and titrating PCSK9 inhibitors in eligible patients to achieve optimal low-density lipoprotein cholesterol reduction and cardiovascular risk management.</p></list-item><list-item><p>Select appropriate strategies for managing adverse effects and addressing barriers to adherence in patients receiving PCSK9 inhibitors.</p></list-item><list-item><p>Collaborate with specialists, clinical pharmacists, and other members of the interprofessional team to optimize patient care and ensure comprehensive management of hypercholesterolemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37376&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37376">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-37376.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an important regulator of cholesterol metabolism.&#x000a0;In the United States, 2 fully humanized monoclonal antibodies&#x02014;alirocumab and evolocumab&#x02014; have been approved by the US Food and Drug Administration (FDA) to inhibit or reduce PCSK9 activity.<xref ref-type="bibr" rid="article-37376.r1">[1]</xref><xref ref-type="bibr" rid="article-37376.r2">[2]</xref>&#x000a0;Recently, both the European Union and FDA have approved inclisiran, a small interfering mRNA, to inhibit intracellular PCSK9 synthesis.<xref ref-type="bibr" rid="article-37376.r3">[3]</xref><xref ref-type="bibr" rid="article-37376.r4">[4]</xref><xref ref-type="bibr" rid="article-37376.r5">[5]</xref></p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>The FDA has approved alirocumab&#x000a0;for adults with an established or high risk of cardiovascular disease and adults with familial hypercholesterolemia.</p>
        <list list-type="bullet">
          <list-item>
            <p>To reduce the risk of myocardial infarction (MI), stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As an adjunct to diet, alone or in combination with other low-density lipoprotein (LDL) cholesterol (LDL-C)&#x02013;lowering therapies, for treating adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia, to reduce LDL-C.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As an adjunct to diet and other LDL-C&#x02013;lowering therapies in adults with homozygous familial hypercholesterolemia to reduce LDL-C.</p>
          </list-item>
        </list>
        <p>The FDA has approved evolocumab&#x000a0;for use in adults with an established or high risk of cardiovascular disease risk, as well as in both adults and pediatric patients aged 10 or older with familial hypercholesterolemia.</p>
        <list list-type="bullet">
          <list-item>
            <p>To reduce the risk of MI, stroke, and coronary revascularization in adults with established cardiovascular disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As an adjunct to diet, alone or combined with other LDL-C&#x02013;lowering therapies for treating adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia to reduce LDL-C.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As an adjunct to diet and other LDL-C&#x02013;lowering therapies in pediatric patients aged 10 and older with heterozygous familial hypercholesterolemia, to reduce LDL-C.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As an adjunct to other LDL-C-lowering&#x02013;therapies in adults and pediatric patients aged 10 and older with homozygous familial hypercholesterolemia, to reduce LDL-C.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As an adjunct to diet and maximally tolerated statin therapy&#x000a0;to treat adults with heterozygous familial hypercholesterolemia who require additional lowering of LDL-C.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>As an adjunct to diet and maximally tolerated statin therapy&#x000a0;to treat adults with clinical atherosclerotic cardiovascular disease who require additional lowering of LDL-C.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-37376.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>PCSK9 has emerged as an important regulator of cholesterol metabolism.<xref ref-type="bibr" rid="article-37376.r2">[2]</xref>&#x000a0;Increased PCSK9 activity correlates with heightened LDL-C levels, while specific gain-of-function mutations lead to autosomal dominant familial hypercholesterolemia characterized by extremely high total and LDL-C levels, premature atherosclerotic vascular disease, and the formation of tendon xanthomas.<xref ref-type="bibr" rid="article-37376.r6">[6]</xref><xref ref-type="bibr" rid="article-37376.r7">[7]</xref>&#x000a0;Conversely, individuals with reduced PCSK9 activity, whether&#x000a0;due to&#x000a0;genetic polymorphism or the administration of PCSK9 monoclonal antibodies, exhibit lower cholesterol levels and a reduced risk of cardiovascular disease.<xref ref-type="bibr" rid="article-37376.r8">[8]</xref></p>
        <p>
<bold>Normal Cholesterol Metabolism</bold>
</p>
        <p>LDL-C is normally cleared from the circulation as apoprotein B100 on the surface of LDL and binds to LDL receptors on hepatic and extrahepatic tissues. LDL bound to&#x000a0;these receptors undergoes a process of endocytosis. The endocytic vesicle fuses with lysosomes, increasing the intracellular concentration of free cholesterol. As the intracellular concentration of cholesterol increases,&#x000a0;3 events occur, as mentioned below.<xref ref-type="bibr" rid="article-37376.r9">[9]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Decreased activity of 3-hydroxy-3-methylglutaryl coenzyme AHMG-CoA reductase&#x02014;the rate-limiting enzyme of cholesterol synthesis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Activation of acyl-coenzyme A:cholesterol acyltransferase (ACAT)&#x02014;an enzyme that increases cholesterol storage as a cholesterol ester.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Reduced expression of LDL receptors on the cell surface.</p>
          </list-item>
        </list>
        <p>In this highly integrated system, as the cell takes up more cholesterol by this normal LDL-receptor pathway, de novo production of cholesterol decreases, and less is taken up by the LDL receptors. When LDL levels are particularly&#x000a0;high or undergo modification, such as glycation or oxidation, they are more apt to be taken up by the scavenger pathway on endothelial cells, leading to the development of atherosclerotic plaques and vascular disease.</p>
        <p>An important concept to recognize is that LDL receptors continually recycle back to the cell surface, where they bind and clear more LDL-C. PCSK9, a product of hepatocytes, is secreted into the plasma, where it binds to the LDL receptors, facilitating their lysosomal degradation. Thus, PCSK9 reduces the expression of LDL receptors on the cell membrane,&#x000a0;decreasing the clearance of LDL-C.</p>
        <p>Statins decrease HMG-CoA reductase activity, reducing cholesterol synthesis. Reduced intracellular cholesterol leads to increased recycling and the expression of LDL receptors on the cell surface. This, in turn, allows for increased clearance of LDL-C by&#x000a0;the non-atherogenic receptor-mediated pathway, leaving less LDL to be taken up by the scavenger pathway. Statins increase the activity of PCSK9. While statins effectively decrease cholesterol levels, their efficacy is diminished by this increase in PCSK9 activity.</p>
        <p>
<bold>PCSK9 </bold>
</p>
        <p>Familial hypercholesterolemia is characterized by high total and LDL-C levels, premature vascular disease, and tendon xanthomas. In most cases, this is due to a genetic mutation of the LDL receptor caused by mutations of the apoprotein&#x000a0;<italic toggle="yes">B100</italic>&#x000a0;or&#x000a0;<italic toggle="yes">PCSK9</italic>&#x000a0;genes. In 2003, researchers reported a family in France with the familial hypercholesterolemia phenotype without an identifiable mutation of the LDL receptor or apoprotein B100.<xref ref-type="bibr" rid="article-37376.r10">[10]</xref>&#x000a0;Affected family members were discovered to have a gain of function mutation of a serine protease, PCSK9. Transgenic mice overexpressing PCSK9 have reduced LDL-R function and elevated LDL, while PCSK9 knockout mice have increased LDL-R activity and low LDL-C levels. A longitudinal epidemiologic study found subjects with loss of function mutations in PCSK9 had a modest reduction in LDL-C but a more significant decrease in coronary heart disease.<xref ref-type="bibr" rid="article-37376.r11">[11]</xref></p>
        <p>Understanding these basic principles of cholesterol metabolism led to the hypothesis that measures to reduce PCSK9 activity would lower LDL-C levels and possibly reduce the risk of cardiovascular disease.&#x000a0;Three&#x000a0;pharmaceutical products in the United States reduce PCSK9 activity: alirocumab, evolocumab, and inclisiran.&#x000a0;Alirocumab and evolocumab are fully humanized monoclonal antibodies injected subcutaneously at intervals every 2 to 4 weeks, effectively lowering total and LDL-C. Whether used as monotherapy or combined with a statin, they typically reduce LDL-C levels by 50% to 60%. The effect is sustained as long as treatment continues.<xref ref-type="bibr" rid="article-37376.r12">[12]</xref><xref ref-type="bibr" rid="article-37376.r13">[13]</xref><xref ref-type="bibr" rid="article-37376.r14">[14]</xref>&#x000a0;Inclisiran is a small interfering mRNA that inhibits the intracellular synthesis of PCSK9. When administered to patients on maximally tolerated statin therapy, inclisiran reduces LDL-C by 50%.<xref ref-type="bibr" rid="article-37376.r4">[4]</xref><xref ref-type="bibr" rid="article-37376.r5">[5]</xref></p>
      </sec>
      <sec id="article-37376.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms, Strengths, and Dosages</bold>
</p>
        <p><bold>Alirocumab:</bold>&#x000a0;Alirocumab offers flexible dosing options, as mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Alirocumab is supplied in a 75- or 150-mg single-dose prefilled pen.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The recommended starting dosage is 75 mg every&#x000a0;2 weeks, administered subcutaneously.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>An alternative starting dosage regimen is 300 mg every&#x000a0;4 weeks.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>If the LDL-C response is inadequate, the dosage may be adjusted to the maximum dosage of 150 mg administered every&#x000a0;2 weeks.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>No pediatric dosing is recommended for this drug.</p>
          </list-item>
        </list>
        <p>&#x000a0;<bold>Evolocumab: </bold>Evolocumab&#x000a0;offers flexible dosing options, as mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Evolocumab is supplied as a 140 mg/mL single-use prefilled syringe or autoinjector and a 420 mg/3.5 mL solution in a single-use infusor with a prefilled cartridge.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For adults, the dosing is 140 mg every&#x000a0;2 weeks or 420 mg monthly, administered subcutaneously.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The 420 mg dose can be administered over 5 minutes using the single-use infusor or by consecutively giving 3 140 mg injections within 30 minutes.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For children aged 10 and older with heterozygous familial hypercholesterolemia, dosing is 140 mg subcutaneously every&#x000a0;2 weeks or 420 mg subcutaneously monthly.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For adults and children aged 10 and older with homozygous familial hypercholesterolemia, the dosage is 420 mg subcutaneously&#x000a0;monthly but can be increased to 420 mg every 2 weeks if a clinically meaningful response is not achieved in 12 weeks.</p>
          </list-item>
        </list>
        <p><bold>Inclisiran: </bold>The recommended dosage option for inclisiran is mentioned below.</p>
        <list list-type="bullet">
          <list-item>
            <p>Inclisiran is supplied in a 284 mg/1.5 mL prefilled syringe.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The recommended dosage of inclisiran&#x000a0;consists of a 284-mg subcutaneous injection initially, followed by a second dose at 3 months, and subsequent doses every 6 months thereafter.</p>
          </list-item>
        </list>
        <p>No dosage adjustment is necessary for patients with mild or moderately impaired hepatic or renal function. However, currently, no available data exist on the use of alirocumab, evolocumab, and inclisiran in patients with severe hepatic dysfunction. Specifically for alirocumab, there is a lack of data regarding patients with severe renal impairment, and for inclisiran, data are unavailable for those with end-stage renal disease.</p>
        <p>
<bold>Efficacy of the Drugs</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Decreases LDL-C by 45% to 65%.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Decreases apoprotein B by 40% to 50%.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Decreases lipoprotein&#x000a0;(a) by 30% to 40%.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Decreases triglyceride by 8% to 10%.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increases HDL cholesterol by 8% to 10%.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Increases apoprotein A1 by 4% to 5%.<xref ref-type="bibr" rid="article-37376.r12">[12]</xref><xref ref-type="bibr" rid="article-37376.r15">[15]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Outcomes data</bold>
</p>
        <p>Short- and long-term studies have shown a significant reduction in cardiovascular events with alirocumab and evolocumab.<xref ref-type="bibr" rid="article-37376.r2">[2]</xref><xref ref-type="bibr" rid="article-37376.r15">[15]</xref><xref ref-type="bibr" rid="article-37376.r16">[16]</xref></p>
        <p>Cardiovascular outcomes trials for inclisiran are being conducted, but no published results exist.<xref ref-type="bibr" rid="article-37376.r5">[5]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Intravascular ultrasound evidence of plaque regression in patients on PCSK9 inhibitors (GLAGOV study).<xref ref-type="bibr" rid="article-37376.r17">[17]</xref>
<list list-type="bullet"><list-item><p>Decreased plaque volume and plaque regression in a more significant percentage of treated subjects than with placebo.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Evolocumab versus placebo&#x000a0;for 76 weeks.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>FOURIER (evolocumab): Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk.<xref ref-type="bibr" rid="article-37376.r18">[18]</xref></p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Studied 27,564 subjects aged 40 and older&#x000a0;or&#x000a0;85 and younger with clinically evident cardiovascular disease at high risk for a recurrent event with LDL-C&#x000a0;greater than or equal to 70 mg/dL or non-HDL-C&#x000a0;greater than or equal to&#x000a0;100 mg/dL and triglycerides&#x000a0;less than or equal to&#x000a0;400 mg/dL.</p>
              </list-item>
              <list-item>
                <p>15% reduction in the primary end point, composite of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization, hazard ratio, 0.85; 95% CI, 0.79 to 0.92.</p>
              </list-item>
              <list-item>
                <p>20%&#x000a0;reduction in the secondary end point of cardiovascular death, MI, or stroke, hazard ratio, 0.80; 95% CI, 0.73 to 0.88.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>ODYSSEY (alirocumab): Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab.<xref ref-type="bibr" rid="article-37376.r19">[19]</xref></p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Studied 18,924 subjects aged 40 or older, hospitalized with an acute coronary syndrome 1 to 12 months before randomization, and had an LDL-C of at least 70 mg/dL, a non-HDL-C of at least 100 mg/dL, or an apolipoprotein B level of at least 80 mg/dL.</p>
              </list-item>
              <list-item>
                <p>15%&#x000a0;reduction in the primary end point, a composite of death from coronary heart disease, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization, hazard ratio, 0.85; 95% CI, 0.78 to 0.93</p>
              </list-item>
              <list-item>
                <p>15%&#x000a0;reduction in the secondary end point, and coronary heart disease event, major coronary heart disease events, any cardiovascular event, and a composite of death from any cause, nonfatal MI, or nonfatal ischemic stroke, hazard ratio, 0.85; 95% CI, 0.73 to 0.98.</p>
              </list-item>
              <list-item>
                <p>The absolute benefit was more significant among patients with a baseline LDL level greater than or equal to 100 mg/dL.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <p>
<bold>Cost of the Drugs</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>The drugs are expensive. In the United States, alirocumab and evolocumab are priced at $5,800 to $6,500 annually, whereas inclisiran costs $9,750 for the first year and $6500 annually thereafter.<xref ref-type="bibr" rid="article-37376.r2">[2]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The drugs require prior authorization.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Generally recommended for patients with established or at high risk for cardiovascular disease who cannot achieve adequate lowering of LDL-C with maximally tolerated statin &#x000b1; ezetimibe or who are statin-intolerant.</p>
          </list-item>
        </list>
        <p>The American College of Cardiology and the National Lipid Association 2022 published guidelines on the use of PCSK9 inhibitors and other nonstatin therapies:</p>
        <p>PCSK9 inhibitors are recommended for several patient populations.<xref ref-type="bibr" rid="article-37376.r15">[15]</xref>&#x000a0;These include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>In patients with cardiovascular disease at very high risk whose LDL-C level remains &#x02265;55 mg/dL (&#x02265;1.42 mmol/L) on a maximally tolerated statin, adding a PCSK9 inhibitor is reasonable.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In patients with cardiovascular disease not at very high risk whose LDL-C remains &#x02265;70 mg/dL (&#x02265;1.81 mmol/L) on a maximally tolerated statin, adding a PCSK9 inhibitor is reasonable.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In patients with severe primary hypercholesterolemia (LDL-C level &#x02265;190 mg/dL [&#x02265;4.91 mmol/L]), without familial hypercholesterolemia, if the LDL-C level on statin &#x02265;70 mg/dL (&#x02265;1.81 mmol/L) a PCSK9 inhibitor may be considered.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In patients with severe primary hypercholesterolemia (LDL-C level &#x02265;190 mg/dL [&#x02265;4.91 mmol/L]), with a diagnosis of familial hypercholesterolemia, if the LDL-C level on statin &#x02265;55 mg/dL (&#x02265;1.42 mmol/L) a PCSK9 inhibitor may be considered.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>In patients without clinical cardiovascular disease and with baseline LDL-C &#x02265;190 mg/dL&#x000a0;on a statin for primary prevention, if the LDL-C level on statin &#x02265;100 mg/dL (&#x02265;2.59 mmol/L), a PCSK9 inhibitor may be considered.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>For patients with statin-associated adverse effects, a PCSK9 inhibitor may be considered for those with clinical cardiovascular disease or baseline LDL-C &#x02265;190 mg/dL (&#x02265;4.91 mmol/L).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Inclisiran may be considered in patients who have demonstrated poor adherence to PCSK9 monoclonal antibodies, have adverse effects from both PSCK9 monoclonal antibodies, or cannot adhere to&#x000a0;a&#x000a0;self-injection regimen.</p>
          </list-item>
        </list>
        <p>The specific details of these guidelines formulated by the ACC and NLA are cited in the references at the end of this article.</p>
      </sec>
      <sec id="article-37376.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <p>Adverse effects for each of these agents are mentioned below.<xref ref-type="bibr" rid="article-37376.r15">[15]</xref><xref ref-type="bibr" rid="article-37376.r20">[20]</xref></p>
        <p><bold>Evolocumab:&#x000a0;</bold>Evolocumab may lead to severe reactions such as hypersensitivity reactions and angioedema, while common adverse effects encompass injection site reactions, nasopharyngitis, headache, upper respiratory tract infection, musculoskeletal pain, back pain, elevated blood pressure, diarrhea, and myalgia.</p>
        <p><bold>Alirocumab:&#x000a0;</bold>Alirocumab may induce severe reactions such as hypersensitivity reactions, hypersensitivity vasculitis, and angioedema, while common adverse effects include generally mild injection-site reactions, nasopharyngitis, diarrhea, bronchitis, myalgia, muscle spasms, elevated alanine transaminase (ALT) or aspartate transaminase (AST) levels, confusion, and musculoskeletal pain.</p>
        <p><bold>Inclisiran:&#x000a0;</bold>No severe adverse events have yet been reported for inclisiran. Common reactions encompass injection site reactions, arthralgia, urinary tract infections, diarrhea, bronchitis, extremity pain, and dyspnea.</p>
      </sec>
      <sec id="article-37376.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Alirocumab&#x000a0;and&#x000a0;evolocumab&#x000a0;are contraindicated in patients with a history of hypersensitivity reactions to either of the agents. Caution is advised in giving evolocumab to patients with latex hypersensitivity. No contraindications are listed for inclisiran.<xref ref-type="bibr" rid="article-37376.r15">[15]</xref>&#x000a0;None of these agents currently have any significant drug-drug interactions listed.<xref ref-type="bibr" rid="article-37376.r21">[21]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-37376.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>The prescriber should recheck the LDL-C after starting alirocumab, evolocumab, or inclisiran treatment. Inclisiran is dosed at&#x000a0;284 mg every 6 months. Evolocumab&#x000a0;dosing is 140 mg every&#x000a0;2 weeks or 420 mg monthly alirocumab&#x000a0;usually&#x000a0;is started at a dose of 75 mg every&#x000a0;2 weeks. After 4 to 8 weeks, repeat an LDL-C level.&#x000a0;If the LDL-C response is not adequate, increase the dose to a maximum dosage of 150 mg every&#x000a0;2 weeks. Following the dose adjustment, remeasure the LDL-C level after 4 to 8 weeks.<xref ref-type="bibr" rid="article-37376.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-37376.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Due to the cost implications associated with PCSK9 inhibitors and inclisiran, collaborative efforts among clinicians, clinical pharmacists, and specialty pharmacies are paramount to ensure patient adherence to therapy. This collaboration may entail various tasks, such as completing financial assistance paperwork, submitting prior authorizations, or acquiring manufacturer discount cards to facilitate patient access to treatment. A specialized team consisting of nurses, pharmacists, and prescribers must work collectively to ensure the safe administration of these drugs, monitor laboratory values and adverse effects, and provide comprehensive education to patients and their families. Pharmacists, including those specialized in cardiology, can provide valuable insights to prescribers regarding dosing and administration intervals. By leveraging this interprofessional approach, these novel agents can effectively achieve their therapeutic objectives, particularly in patients who have not responded adequately to statin therapy.<xref ref-type="bibr" rid="article-37376.r22">[22]</xref><xref ref-type="bibr" rid="article-37376.r23">[23]</xref></p>
      </sec>
      <sec id="article-37376.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=37376&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=37376">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/37376/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=37376">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-37376.s10">
        <title>References</title>
        <ref id="article-37376.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Jacobson</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Saseen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Gotto</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Underberg</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.</article-title>
            <source>J Clin Lipidol</source>
            <year>2017</year>
            <season>Jul-Aug</season>
            <volume>11</volume>
            <issue>4</issue>
            <fpage>880</fpage>
            <page-range>880-890</page-range>
            <pub-id pub-id-type="pmid">28532784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Tobert</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Targeting PCSK9 With Antibodies and Gene Silencing to Reduce LDL Cholesterol.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2023</year>
            <month>Mar</month>
            <day>10</day>
            <volume>108</volume>
            <issue>4</issue>
            <fpage>784</fpage>
            <page-range>784-790</page-range>
            <pub-id pub-id-type="pmid">36469793</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Aguilar-Salinas</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>G&#x000f3;mez-D&#x000ed;az</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Corral</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>New Therapies for Primary Hyperlipidemia.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2022</year>
            <month>Apr</month>
            <day>19</day>
            <volume>107</volume>
            <issue>5</issue>
            <fpage>1216</fpage>
            <page-range>1216-1224</page-range>
            <pub-id pub-id-type="pmid">34888679</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ray</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Landmesser</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Leiter</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Kallend</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dufour</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Karakas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Troquay</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Visseren</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Wijngaard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Apr</month>
            <day>13</day>
            <volume>376</volume>
            <issue>15</issue>
            <fpage>1430</fpage>
            <page-range>1430-1440</page-range>
            <pub-id pub-id-type="pmid">28306389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giordano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Polimeni</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Indolfi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spaccarotella</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent.</article-title>
            <source>Curr Opin Lipidol</source>
            <year>2023</year>
            <month>Aug</month>
            <day>01</day>
            <volume>34</volume>
            <issue>4</issue>
            <fpage>133</fpage>
            <page-range>133-140</page-range>
            <pub-id pub-id-type="pmid">36924354</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Two Novel Disease-Causing Mutations in the LDLR of Familial Hypercholesterolemia.</article-title>
            <source>Front Genet</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>762587</fpage>
            <pub-id pub-id-type="pmid">34970301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Taranto</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Giacobbe</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fortunato</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Familial hypercholesterolemia: A complex genetic disease with variable phenotypes.</article-title>
            <source>Eur J Med Genet</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>103831</fpage>
            <pub-id pub-id-type="pmid">31883481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ji</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases.</article-title>
            <source>Int J Mol Sci</source>
            <year>2021</year>
            <month>May</month>
            <day>28</day>
            <volume>22</volume>
            <issue>11</issue>
            <pub-id pub-id-type="pmid">34071276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldstein</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>MS</given-names>
              </name>
            </person-group>
            <article-title>The LDL receptor.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>431</fpage>
            <page-range>431-8</page-range>
            <pub-id pub-id-type="pmid">19299327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Amsellem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abifadel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trillard</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Devillers</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Luc</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Krempf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reznik</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Girardet</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Fredenrich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Junien</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Varret</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Boileau</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Benlian</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rab&#x000e8;s</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.</article-title>
            <source>Hum Mutat</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>26</volume>
            <issue>5</issue>
            <fpage>497</fpage>
            <pub-id pub-id-type="pmid">16211558</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Boerwinkle</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mosley</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Hobbs</surname>
                <given-names>HH</given-names>
              </name>
            </person-group>
            <article-title>Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>Mar</month>
            <day>23</day>
            <volume>354</volume>
            <issue>12</issue>
            <fpage>1264</fpage>
            <page-range>1264-72</page-range>
            <pub-id pub-id-type="pmid">16554528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Durairaj</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sabates</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nieves</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Moraes</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Baum</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Its Inhibitors: a Review of Physiology, Biology, and Clinical Data.</article-title>
            <source>Curr Treat Options Cardiovasc Med</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>8</issue>
            <fpage>58</fpage>
            <pub-id pub-id-type="pmid">28639183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stroes</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Colquhoun</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sullivan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Civeira</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rosenson</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Watts</surname>
                <given-names>GF</given-names>
              </name>
              <name>
                <surname>Bruckert</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dent</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Knusel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Xue</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Rocco</surname>
                <given-names>M</given-names>
              </name>
              <collab>GAUSS-2 Investigators</collab>
            </person-group>
            <article-title>Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2014</year>
            <month>Jun</month>
            <day>17</day>
            <volume>63</volume>
            <issue>23</issue>
            <fpage>2541</fpage>
            <page-range>2541-2548</page-range>
            <pub-id pub-id-type="pmid">24694531</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koren</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Langslet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Kassahun</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ruzza</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Somaratne</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Raal</surname>
                <given-names>FJ</given-names>
              </name>
            </person-group>
            <article-title>Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.</article-title>
            <source>JAMA Cardiol</source>
            <year>2017</year>
            <month>Jun</month>
            <day>01</day>
            <volume>2</volume>
            <issue>6</issue>
            <fpage>598</fpage>
            <page-range>598-607</page-range>
            <pub-id pub-id-type="pmid">28291870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>Writing Committee</collab>
              <name>
                <surname>Lloyd-Jones</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Ballantyne</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Birtcher</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Covington</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Minissian</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Orringer</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Waring</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Wilkins</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2022</year>
            <month>Oct</month>
            <day>04</day>
            <volume>80</volume>
            <issue>14</issue>
            <fpage>1366</fpage>
            <page-range>1366-1418</page-range>
            <pub-id pub-id-type="pmid">36031461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandts</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Clinical implications and outcomes of the ORION Phase III&#x000a0;trials.</article-title>
            <source>Future Cardiol</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>5</issue>
            <fpage>769</fpage>
            <page-range>769-777</page-range>
            <pub-id pub-id-type="pmid">33345605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicholls</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Puri</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ballantyne</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kastelein</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Somaratne</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kassahun</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ungi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Podolec</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ophuis</surname>
                <given-names>AO</given-names>
              </name>
              <name>
                <surname>Cornel</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Borgman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nissen</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.</article-title>
            <source>JAMA</source>
            <year>2016</year>
            <month>Dec</month>
            <day>13</day>
            <volume>316</volume>
            <issue>22</issue>
            <fpage>2373</fpage>
            <page-range>2373-2384</page-range>
            <pub-id pub-id-type="pmid">27846344</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Keech</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Honarpour</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wiviott</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Kuder</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>TR</given-names>
              </name>
              <collab>FOURIER Steering Committee and Investigators</collab>
            </person-group>
            <article-title>Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>May</month>
            <day>04</day>
            <volume>376</volume>
            <issue>18</issue>
            <fpage>1713</fpage>
            <page-range>1713-1722</page-range>
            <pub-id pub-id-type="pmid">28304224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwartz</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Steg</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Szarek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Bittner</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Edelberg</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Hanotin</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Harrington</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Jukema</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Lecorps</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mahaffey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Moryusef</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pordy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Quintero</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Roe</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Sasiela</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Tamby</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Tricoci</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Zeiher</surname>
                <given-names>AM</given-names>
              </name>
              <collab>ODYSSEY OUTCOMES Committees and Investigators</collab>
            </person-group>
            <article-title>Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Nov</month>
            <day>29</day>
            <volume>379</volume>
            <issue>22</issue>
            <fpage>2097</fpage>
            <page-range>2097-2107</page-range>
            <pub-id pub-id-type="pmid">30403574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Giugliano</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Mach</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zavitz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kurtz</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kanevsky</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Schneider</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Keech</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Sabatine</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Honarpour</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wasserman</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Ott</surname>
                <given-names>BR</given-names>
              </name>
              <collab>EBBINGHAUS Investigators</collab>
            </person-group>
            <article-title>Cognitive Function in a Randomized Trial of Evolocumab.</article-title>
            <source>N Engl J Med</source>
            <year>2017</year>
            <month>Aug</month>
            <day>17</day>
            <volume>377</volume>
            <issue>7</issue>
            <fpage>633</fpage>
            <page-range>633-643</page-range>
            <pub-id pub-id-type="pmid">28813214</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mo&#x0015f;teoru</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gai&#x00163;&#x00103;</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Banach</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>An update on PCSK9 inhibitors- pharmacokinetics, drug interactions, and toxicity.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>16</volume>
            <issue>12</issue>
            <fpage>1199</fpage>
            <page-range>1199-1205</page-range>
            <pub-id pub-id-type="pmid">32966148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Atanda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Stubbings</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Groo</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Implementation of a New Clinic-Based, Pharmacist-Managed PCSK9 Inhibitor Consultation Service.</article-title>
            <source>J Manag Care Spec Pharm</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>23</volume>
            <issue>9</issue>
            <fpage>918</fpage>
            <page-range>918-925</page-range>
            <pub-id pub-id-type="pmid">28854074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-37376.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaufman</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Warden</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Minnier</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Miles</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Duell</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Purnell</surname>
                <given-names>JQ</given-names>
              </name>
              <name>
                <surname>Wojcik</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fazio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shapiro</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>Application of PCSK9 Inhibitors in Practice.</article-title>
            <source>Circ Res</source>
            <year>2019</year>
            <month>Jan</month>
            <day>04</day>
            <volume>124</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-37</page-range>
            <pub-id pub-id-type="pmid">30605414</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
